Inotuzumab ozogamicin versus FLAG-Ida in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia - real-world resource use data.
Catherine S Y LecatCaroline BesleyRachael E HoughAsim KhwajaCaroline FurnessDavid I MarksAdele K FieldingPublished in: Leukemia & lymphoma (2019)